AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04588155 — intervention group
Intervention type: DEVICE
Intervention: Functional assessment
Description: Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
Study NCT04588155 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment
Description: Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution
Study NCT01029444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )
Description: Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
Study NCT01608451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
Study NCT01608451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj. Progesterone
Description: Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
Study NCT02210091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Description: Pharmacokinetic (PK) analysis of ADVATE
Study NCT02210091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Pharmacokinetic (PK) analysis of BAX 855
Study NCT02210091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Prophylaxis treatment
Study NCT02583490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spectrum 5000Q ECT device (RUL ECT)
Study NCT02583490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spectrum 5000Q ECT device (RUL LAP ECT)
Study NCT01256762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat sodium
Description: Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
Study NCT01256762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
Study NCT00515242 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: relaxing environment
Description: time in a relaxing environment
Study NCT02514824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Investigational mTOR kinase inhibitor
Study NCT00886834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
Study NCT00886834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills which are identical to the study drug in appearance, taste, and smell.
Study NCT01138657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
Study NCT01138657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
Study NCT01138657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
Study NCT01138657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT01357902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
Study NCT01048164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Chair Massage
Study NCT04314258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera tea
Description: 4 grams of Moringa oleifera tea twice daily
Study NCT00382382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diffusion tensor imaging (DTI)
Description: Both groups will have a diffusion tensor imaging (DTI) perform.
Study NCT04647708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive low oral dose of M5049, twice daily in Part A.
Study NCT04647708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive ascending oral dose of M5049, twice daily in Part A.
Study NCT04647708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive high oral dose of M5049, twice daily in Part B.
Study NCT04647708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5049.
Study NCT04622878 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: thrombectomy and PTA
Description: open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
Study NCT02198911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO GUM
Description: For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
Study NCT02198911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCC (Mint Chocolate Chip gum)
Description: For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
Study NCT02198911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C (Cinnamon gum)
Description: For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
Study NCT01256762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
Study NCT04082780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV MMX
Description: Intervention arm
Study NCT04082780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study NCT03199521 — intervention group
Intervention type: OTHER
Intervention: Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
Description: Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
Study NCT02780973 — intervention group
Intervention type: OTHER
Intervention: Wearing of an intraoral device with bovine tooth samples
Description: Wearing of an intraoral device with bovine tooth samples
Study NCT02520739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Virgin Olive Oil (VOO)
Description: VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
Study NCT02520739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optimized High Phenolic Content Oil (OHPCO)
Description: OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
Study NCT02520739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional Olive Oil (FOO)
Description: FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
Study NCT04507165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block+Anterior serratus plane block
Description: Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure.
Study NCT04507165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block+Anterior serratus plane block
Description: Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure.
Study NCT04507165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid free anesthesia
Description: Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h).
Study NCT04507165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid based anesthesia
Description: Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively.
Study NCT04985539 — intervention group
Intervention type: DEVICE
Intervention: Verily Study Watch
Description: Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
Study NCT04243928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping
Description: apply kinesio taping on dorsi flexors muscles
Study NCT04243928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: apply kinesio taping on dorsi flexors muscles
Study NCT02539511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Study NCT02539511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581b
Study NCT02539511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Study NCT02539511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Study NCT03890328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: apply RF therapy to the treatment of splenic trauma
Study NCT03705910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perceptive Rehabilitation
Description: In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas.
Study NCT03705910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilisation Techniques
Description: A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point.
Study NCT01487993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
Study NCT01487993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Lifestyle intervention: 18 months physical therapy and dietary advice
Study NCT01487993 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: Lifestyle intervention: 18 months physical therapy and dietary advice
Study NCT04619277 — intervention group
Intervention type: DEVICE
Intervention: drug-coated balloon
Description: drug-coated balloon
Study NCT01048450 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Joint Resection- Keller Procedure
Description: These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
Study NCT01048450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Fusion
Description: Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
Study NCT01048450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-metallic Joint Implant
Description: Those who had a surgical procedure of a hemi-metallic joint implant
Study NCT00896441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI.
Study NCT04140981 — intervention group
Intervention type: DEVICE
Intervention: ultrasounography
Description: in preoperative period, airway ultrasounagraphy for all patients will be made
Study NCT01065779 — intervention group
Intervention type: DRUG
Intervention: FOSAMAX PLUS
Description: Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
Study NCT01065779 — intervention group
Intervention type: DRUG
Intervention: FOSAMAX PLUS D
Description: Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
Study NCT02476123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)
Description: i.v. administration
Study NCT02313883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioSept(r)
Description: Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Study NCT02313883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PerioSept(r)
Description: Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Study NCT02380898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg ketorolac immediately before induction of anesthesia
Study NCT02380898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 4 mL normal saline 0.9% immediately before induction of anesthesia
Study NCT02393053 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Treatment with subepithelial connective tissue graft (SCTG)
Description: Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
Study NCT02393053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with non-pedicled buccal fat pad graft (BFPG)
Description: Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
Study NCT03698565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve stimulation of the ulnar nerve
Description: The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes.
Study NCT04151849 — intervention group
Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Treatment with GLP-1 agonist for up to 1 year.
Study NCT04151849 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Treatment with SGLT2 inhibitor for up to 1 year
Study NCT03639506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous mitochondria transplantation
Description: inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
Study NCT03639506 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
Description: autologous mitochondria transplantation